Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rachel Rendak"'
Autor:
Francesco Graziano, J. Alan Diehl, Yu Imamura, Les Henderson, Rachel Rendak, Peng Xu, Jens Puschhof, Charles Zou, Sarit Schwartz, Steven A. Carr, Jin Zhou, Philipp Mertins, Xinsen Xu, Masayuki Watanabe, Wei-Li Liao, Eiji Oki, Annamaria Ruzzo, Gabrielle S. Wong, Tianxia Li, Daniel V.T. Catenacci, Jie Bin Liu, Adam J. Bass, Kwok-Kin Wong, Anil K. Rustgi, Steven E. Schumacher, Rameen Beroukhim, Emily O'Day, Shaunt Fereshetian, Kenichi Nakamura, Hideo Baba, David Xu, Zhong Wu, Karin Jensen, Fabiola Cecchi, Austin M. Dulak, Christopher Szeto, James M. McFarland, Todd Hembrough
The role of KRAS, when activated through canonical mutations, has been well established in cancer1. Here we explore a secondary means of KRAS activation in cancer: focal high-level amplification of the KRAS gene in the absence of coding mutations. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e3c1178850c6325e21d376358010496
https://hdl.handle.net/11576/2660415
https://hdl.handle.net/11576/2660415
Autor:
Tianxia Li, Jens Puschhof, Daniel V.T. Catenacci, Austin M. Dulak, Charles Zou, Steven E. Schumacher, Francesco Graziano, David Xu, Adam J. Bass, Kwok-Kin Wong, Rameen Beroukhim, Philipp Mertins, Les Henderson, Karin Jensen, Fabiola Cecchi, Kenichi Nakamura, Hideo Baba, Rachel Rendak, Christopher Szeto, Sarit Schwartz, Steven A. Carr, Peng Xu, James M. McFarland, Anil K. Rustgi, Todd Hembrough, Masayuki Watanabe, Annamaria Ruzzo, Zhong Wu, J. Alan Diehl, Xinsen Xu, Gabrielle S. Wong, Wei-Li Liao, Eiji Oki, Jin Zhou, Jie Bin Liu, Emily O'Day, Shaunt Fereshetian, Yu Imamura
Publikováno v:
Nature Medicine. 24:1627-1627
In the Supplementary Information originally published with this article, a lane was missing in the β-actin blot in Supplementary Fig. 2. The lane has been added. The error has been corrected in the Supplementary Information associated with this arti
Autor:
Namrata Setia, Rachel Rendak, Steven Brad Maron, David Xu, Lindsay Alpert, Daniel V.T. Catenacci, Emily O'Day
Publikováno v:
Journal of Clinical Oncology. 35:60-60
60 Background: Gastroesophageal cancer (GEC) is a global health problem. Multiple phase III anti-EGFR trials of unselected metastatic GEC patients (pts) were negative, yet subset analyses suggested potential benefit in pts with EGFR amplification (am